REPORTING GUIDANCE: A Reported New Federal PrEP Program — What Reporters Should Know
OFF RECORD — NOT FOR PUBLICATION OR ATTRIBUTION
This fact sheet is shared off record for advance planning only. It combines public information with source-reported details that remain unconfirmed and should not be quoted or attributed.
Overview:
Health policy advocates and sources within HHS reported that the Trump administration would possibly announce a new federally driven PrEP program for uninsured people during the opening plenary of the 2026 National Ryan White Conference on HIV Care & Treatment, which took place on Tuesday, August 4.
These sources remain confidential and anonymous to protect their privacy and well-being.
The conference listed HHS Secretary Robert F. Kennedy Jr. as a recorded speaker, and Dr. Jay Bhattacharya, NIH Director and Acting CDC Director, as a plenary speaker. Per sources in the room, RFK Jr. shared remarks via pre-recorded video, and Dr. Bhattacharya spoke in person.
Sources also said that the initiative may involve donated medication from Gilead Sciences, draw on NIH resources to support an implementation science study, and is reportedly called “Ascend.” Those details, however, are not confirmed.
If an announcement is made, we encourage reporters to closely examine its funding, governance, community involvement, and potential effect on the existing HIV-prevention infrastructure. We will share an updated, on-record response once verifiable details are available.
What We’re Hearing:
- The administration could be preparing for a federal PrEP or uninsured-access initiative.
- Gilead may donate medication; the program may use NIH resources to conduct an implementation science study while CDC reportedly may not hold a central role.
- Community organizations, federal PrEP partners, advocates and frontline experts reportedly have not been meaningfully consulted.
- The initiative may be branded “Ascend.”
Reporters should treat each point as source-reported until the administration releases documents or officials confirm the details on the record.
Why Reporters Should Be Cautious:
Expanding PrEP access for uninsured people is important and welcome. But free medication is not the same as access. A functioning program must also account for providers, laboratory services, prescriptions, outreach, navigation and ongoing care—and it must be built with the communities already doing that work.
The first Trump administration followed a similar path in 2019, when Gilead agreed to donate PrEP medication for up to 200,000 uninsured people annually. HHS launched Ready, Set, PrEP and assumed enrollment, distribution and administrative costs. Advocates later called for the program to sunset, arguing it was used by fewer than 10,000 people and that it duplicated manufacturer-assistance programs without creating a complete, community-driven system of care.
The timing raises an additional contradiction: community organizations that connect uninsured people to PrEP are losing long-standing CDC prevention funding (see Stat News), while the government may announce a new program that depends on their outreach and trust. If NIH money is being redirected, the CDC is sidelined, or if Ryan White Program infrastructure is used, the administration should explain what existing research, prevention, or care resources may be affected.
The money trail also matters. A pharmaceutical donation can still generate public costs and private benefits. Reporters should determine whether Gilead or participating intermediaries will receive federal payments, subsidies, tax advantages, exclusivity, data access or other consideration.
Suggested Reporter Follows:
- What does the program cover beyond medication, who qualifies, and which PrEP products are included?
- What is its legal authority, budget, funding source and operating agency?
- Are NIH funds being redirected—and, if so, from which institutes, grants or research priorities?
- What roles will CDC, HRSA and the Ryan White HIV/AIDS Program play? Could existing funding or infrastructure be displaced?
- Does Dr. Jay Bhattacharya’s dual role as NIH Director and Acting CDC Director create conflicts or enable CDC to be excluded from its traditional HIV-prevention role?
- Does this announcement distract from the administration’s decision not to renew CDC’s long-standing community HIV-prevention program, PS21-2102? Will affected organizations receive direct support for outreach and navigation?
- Which community organizations and PrEP users were consulted? How does the process honor the Denver Principles and the self-determination of people living with or vulnerable to HIV?
- What public payments or benefits will flow to Gilead or intermediaries, and what evaluation of Ready, Set, PrEP informed the new design?
Story Framing:
This story is not simply whether the government is offering free PrEP. It is whether the administration is building a durable and effective pathway to HIV prevention—or repeating a medication-first model while weakening the community infrastructure needed to make it work. Until documents are available, reporters should avoid calling the initiative “comprehensive,” “historic” or a “national solution.” The name “Ascend,” a new Gilead donation, use of NIH funds and CDC’s role should remain clearly attributed or described as unconfirmed.
Public context: HHS announced the prior Gilead donation in 2019 and agreed to cover distribution-related costs. PrEP4All and partner advocates supported sunsetting Ready, Set, PrEP in 2024 and called for a comprehensive national program. The published Ryan White conference agenda listed the opening plenary for 3:00 p.m. ET on Tuesday, August 4, 2026.
Source-reported and unconfirmed: The new program’s existence and design; the name “Ascend”; Gilead’s role; the use of NIH funds; the CDC’s role; and any effect on Ryan White funding or infrastructure.
###
PrEP Fast Facts from PrEP4All:
- PrEP prevents HIV: Pre-exposure prophylaxis (PrEP) is a daily pill or long-acting medication that reduces the risk of acquiring HIV from sex by about 99% when taken as prescribed, making it one of the most effective HIV prevention tools ever developed.
- Federally funded research has opened the door to ending new HIV transmissions: Scientific advances have made ending the HIV epidemic more achievable than ever, but access — not science — remains the biggest barrier.
- Too many people still can't access PrEP: Despite more than a decade of FDA-approved PrEP, significant racial, gender and economic disparities persist, with Black, Latino and other underserved communities far less likely to receive PrEP than those who could benefit.
- Federal HIV prevention funding is under attack: undermining global and domestic access to this life-saving intervention.
- PrEP4All is fighting for a National PrEP Program: PrEP4All is leading the effort to establish a federally funded National PrEP Program so uninsured and underinsured people can access PrEP, laboratory services, and related care regardless of their ability to pay.
- HIV prevention is a human right: Everyone, regardless of race, gender, income or geography, should have equitable access to lifesaving HIV prevention and treatment, because ending the HIV epidemic requires universal access.
Learn more at PrEP4All.org
About PrEP4All: PrEP4All is a national advocacy organization founded in 2018 and led by patients, healthcare professionals, and policy experts working to expand access to lifesaving HIV prevention and treatment. Grounded in lived experience and inspired by the legacy of ACT UP, PrEP4All uses direct action, media, and policy advocacy to lower drug costs and advance a national strategy to end the HIV epidemic in the United States.
